Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26143786 | 0.70 | KMT2A (0.55) | HSD17B10KDM4EALDH1A1TSHRMAPT | |
| SCHEMBL18292493 | 0.70 | PLAU (0.46) | TBK1ALDH1A1PLAUHTT | |
| SCHEMBL1733580 | 0.67 | HPGD (0.65) | TBK1ADORA1ADORA2AHSD17B10KDM4E | |
| SCHEMBL16101357 | 0.65 | TBK1 (0.47) | TBK1ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL16793164 | 0.65 | L3MBTL1 (0.47) | TBK1HSD17B10KDM4EALDH1A1MAPT | |
| SCHEMBL6441971 | 0.65 | ADORA1 (0.61) | TBK1ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL6442645 | 0.65 | ADORA1 (0.61) | TBK1ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL3369158 | 0.64 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BHSD17B10ALDH1A1 | |
| SCHEMBL6441330 | 0.64 | ADORA1 (0.69) | ADORA1ADORA2AADORA2BHSD17B10KDM4E | |
| SCHEMBL6381145 | 0.64 | TBK1 (0.50) | TBK1ADORA1HSD17B10KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9903855-B2 | Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-27 | — | — | US | disclosed |
| US-9903855-B2 | Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-27 | — | — | US | disclosed |
| US-9632074-B2 | Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-25 | — | — | US | disclosed |
| US-9632074-B2 | Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160146783-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | UNIV CALIFORNIA (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160146783-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | UNIV CALIFORNIA (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160015709-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
| US-20160015709-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015709-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | LGALS3, IKBKG, IRAK3 | TBK1 12/4885ADORA1 4613/4885ADORA2A 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.